NHS Crawley and NHS Horsham and Mid Sussex CCG
Formulary
 
back
3 Respiratory system
03-04-02 Monoclonal Antibodies

Avelumab Bavencio®
Formulary

Solution for Infusion
  • Indication- treating metastatic Merkel cell carcinoma(TA517)
  • Link  NICE TA517 - Avelumab for treating metastatic Merkel cell carcinoma
     

    Red View adult BNF  View SPC online  View childrens BNF  CDF
    Benralizumab Fasenra®
    Formulary
    • 30mg solution for injection in pre-filled syringe
    • Indication- severe eosinophilic asthma (TA565)
    Link  NICE TA565 Benralizumab for treating severe eosinophilic asthma
     

    Red View adult BNF  View SPC online  View childrens BNF
    Mepolizumab Nucala®
    Formulary

    Injection
  • Indication - severe refractory eosinophilic asthma NICE TA431, Funded by NHS England

  • Link  NICE TA431- Mepolizumab for treating severe refractory eosinophilic asthma- Jan 2017
     

    Red View adult BNF  View SPC online  View childrens BNF  HCD
    Omalizumab Xolair®
    Formulary

    Injection
  • Indication - Asthma - severe, persistent (aged 6+, adults)NICE TA278, Funded by NHS England
  • Indication - previously treated chronic spontaneous urticaria (aged 12+) NICE TA339, Funded by CCG. Prescribing would be by specialists in dermatology, immunology or allergy, and notification of initiation will be via the Blueteq initiation and continuation forms.

  • Link  NICE TA339 Omalizumab for previously treated chronic spontaneous urticaria
    Link  MHRA Drug Safety Update Feb 2011 - Omalizumab: potential risk of arterial thrombotic events
    Link  NICE TA278 - Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201)
    Link  NICE TA133 - Omalizumab for severe persistent allergic asthma (Replaced by TA278) - Nov 2007
    Link  NICE TA201 - Omalizumab for the treatment of severe persistent allergic asthma in children aged 611 - Oct 2010 (Updated by TA278)
    Link  PCN 188-2016 Omalizumab for previously treated chronic spontaneous urticaria
     

    Red View adult BNF  View SPC online  View childrens BNF  HCD
    Reslizumab Cinqaero®
    Formulary

    Injection
  • NHSE funded
  • Indication- severe eosinophilic asthma NICE TA479

  • Link  NICE TA479 - Reslizumab for treating severe eosinophilic asthma
     

    Red View adult BNF  View SPC online  View childrens BNF  HCD